Biogen (BIIB) Leerink Global Healthcare Conference 2026 summary

Strategic initiatives and organizational evolution

• Established a West Coast Hub through acquisition, integrating the HI-Bio team and expanding rapidly from 45 to over 100 employees in the past year.

• The hub connects with a bicoastal research pipeline focused on immunology, leveraging both West and East Coast teams.

• Emphasis on maintaining a startup culture within a larger organization to enable agility and innovation.

Lead asset development and clinical progress

• Felzartamab, a targeted anti-CD38 therapy, is being advanced in four main indications: AMR, MVI, IgAN, and PMN, with additional indications in planning.

• Three phase III studies launched in the past year, with AMR as the lead indication due to compelling phase II results.

• AMR phase III trial is global, enrolling 120 patients, with a primary endpoint at six months and a top-line readout expected next year.

• MVI phase II study has begun, targeting 81 patients, and may be registration enabling.

• IgAN and PMN phase III trials are underway, with IgAN targeting a large population and PMN focusing on high-risk, autoantibody-positive patients.

Market opportunity and competitive landscape

• AMR represents a $2 billion+ market in the U.S. with about 11,000 eligible patients; pricing analogs suggest potential for blockbuster status.

• IgAN has an estimated U.S. population of at least 130,000, while PMN has about 36,000; both are sizable rare disease markets.

• Current standard of care in AMR is limited to plasmapheresis and IVIG, with no approved therapies; felzartamab is differentiated by targeting both antibody-producing and NK cells.

• Competitive therapies in IgAN and PMN include SGLT2 inhibitors, complement inhibitors, and anti-CD20s, but felzartamab offers potential for durable, non-chronic treatment.